Actively Recruiting
Integrating Telehealth to Advance Lung Cancer Screening
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-05-29
6000
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating how telehealth methods can improve shared decision-making (SDM) visits before lung cancer screening (LCS) among adults aged 50 to 80 who have a history of smoking. This pragmatic trial seeks to find out if telehealth outreach increases SDM visit completion and whether these strategies work equally well across different races and sexes. The study uses a Sequential Multiple Assignment Randomized Trial (SMART) design with two stages of interventions. Participants receive outreach letters inviting them to schedule an SDM visit either via telehealth only or with the option of telehealth or in-person visits. If they do not respond within 30 days, they receive text message reminders either alone (low-touch strategy) or combined with phone-based digital care coordination (high-touch strategy). Four different intervention arms combine these approaches in various ways to compare their effectiveness. Participants are involved through outreach, scheduling and completing SDM visits, and receiving reminders or coordination calls if needed. Researchers measure the completion of SDM visits within 90 days and follow up with lung cancer screening using low-dose computed tomography (LDCT) at six months. The trial aims to assess the equity and effectiveness of telehealth outreach strategies for lung cancer screening decision-making over a multi-year period.
CONDITIONS
Brief Title
Integrating Telehealth to Advance Lung Cancer Screening
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 50 to 80 years
- History of tobacco use with 20 pack-year or greater smoking history documented or self-reported
- Currently smoke or formerly smoked cigarettes
- No history of lung cancer
- No lung cancer screening in the 24 months before enrollment
- Completed at least one primary care visit at Penn Medicine in the past 3 years
You will not qualify if you...
- Does not meet all inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for eligibility assessment
Duration - Up to 30 days
Participants receive outreach letters inviting them to schedule a shared decision-making (SDM) visit either via telehealth only or telehealth/in-person options to discuss lung cancer screening.
1 to 2 visits depending on scheduling and participant response
Duration - Up to 60 days following the initial outreach
For participants who do not schedule an SDM visit within 30 days, asynchronous text message reminders are sent, with some participants also receiving phone-based digital care coordination to encourage SDM visit completion.
Multiple asynchronous contacts via text and phone
Duration - Up to 6 months after randomization
Participants are observed for completion of low-dose computed tomography (LDCT) screening after the SDM visit.
No specific visits required; monitoring occurs through routine healthcare data
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
K
Katharine Rendle, PhD
H
Hannah Toneff, MSW, MA
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
4